Inhalation CDMO Industry Research Report 2025

Summary

According to APO Research, The global Inhalation CDMO market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Inhalation CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Inhalation CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Inhalation CDMO is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Inhalation CDMO include Aptar Pharma, Bend Bioscience, Bespak, Catalent, CritiTech, Enteris Biopharma, Experic, HCmed and Hovione, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Inhalation CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inhalation CDMO.
The Inhalation CDMO market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Inhalation CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Inhalation CDMO Segment by Company

Aptar Pharma
Bend Bioscience
Bespak
Catalent
CritiTech
Enteris Biopharma
Experic
HCmed
Hovione
Iconovo
Kindeva
Lonza
Particle Sciences
Proveris
Recipharm
Renejix
Ritedose
Vectura
Sanner
Inhalation CDMO Segment by Type

Soft Mist Inhalers (SMIs)
Dry Powder Inhalers (DPIs)
Metered Dose Inhalers (MDIs)
Others
Inhalation CDMO Segment by Application

Commercial
Academic Research
Others
Inhalation CDMO Segment by Application

Commercial
Academic Research
Others
Inhalation CDMO Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhalation CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inhalation CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhalation CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Inhalation CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Inhalation CDMO by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Soft Mist Inhalers (SMIs)
2.2.3 Dry Powder Inhalers (DPIs)
2.2.4 Metered Dose Inhalers (MDIs)
2.2.5 Others
2.3 Inhalation CDMO by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Commercial
2.3.3 Academic Research
2.3.4 Others
2.4 Assumptions and Limitations
3 Inhalation CDMO Breakdown Data by Type
3.1 Global Inhalation CDMO Historic Market Size by Type (2020-2025)
3.2 Global Inhalation CDMO Forecasted Market Size by Type (2026-2031)
4 Inhalation CDMO Breakdown Data by Application
4.1 Global Inhalation CDMO Historic Market Size by Application (2020-2025)
4.2 Global Inhalation CDMO Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Inhalation CDMO Market Perspective (2020-2031)
5.2 Global Inhalation CDMO Growth Trends by Region
5.2.1 Global Inhalation CDMO Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Inhalation CDMO Historic Market Size by Region (2020-2025)
5.2.3 Inhalation CDMO Forecasted Market Size by Region (2026-2031)
5.3 Inhalation CDMO Market Dynamics
5.3.1 Inhalation CDMO Industry Trends
5.3.2 Inhalation CDMO Market Drivers
5.3.3 Inhalation CDMO Market Challenges
5.3.4 Inhalation CDMO Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Inhalation CDMO Players by Revenue
6.1.1 Global Top Inhalation CDMO Players by Revenue (2020-2025)
6.1.2 Global Inhalation CDMO Revenue Market Share by Players (2020-2025)
6.2 Global Inhalation CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Inhalation CDMO Head Office and Area Served
6.4 Global Inhalation CDMO Players, Product Type & Application
6.5 Global Inhalation CDMO Manufacturers Established Date
6.6 Global Inhalation CDMO Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Inhalation CDMO Market Size (2020-2031)
7.2 North America Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Inhalation CDMO Market Size by Country (2020-2025)
7.4 North America Inhalation CDMO Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Inhalation CDMO Market Size (2020-2031)
8.2 Europe Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Inhalation CDMO Market Size by Country (2020-2025)
8.4 Europe Inhalation CDMO Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Inhalation CDMO Market Size (2020-2031)
9.2 Asia-Pacific Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Inhalation CDMO Market Size by Country (2020-2025)
9.4 Asia-Pacific Inhalation CDMO Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Inhalation CDMO Market Size (2020-2031)
10.2 South America Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Inhalation CDMO Market Size by Country (2020-2025)
10.4 South America Inhalation CDMO Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Inhalation CDMO Market Size (2020-2031)
11.2 Middle East & Africa Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Inhalation CDMO Market Size by Country (2020-2025)
11.4 Middle East & Africa Inhalation CDMO Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Aptar Pharma
12.1.1 Aptar Pharma Company Information
12.1.2 Aptar Pharma Business Overview
12.1.3 Aptar Pharma Revenue in Inhalation CDMO Business (2020-2025)
12.1.4 Aptar Pharma Inhalation CDMO Product Portfolio
12.1.5 Aptar Pharma Recent Developments
12.2 Bend Bioscience
12.2.1 Bend Bioscience Company Information
12.2.2 Bend Bioscience Business Overview
12.2.3 Bend Bioscience Revenue in Inhalation CDMO Business (2020-2025)
12.2.4 Bend Bioscience Inhalation CDMO Product Portfolio
12.2.5 Bend Bioscience Recent Developments
12.3 Bespak
12.3.1 Bespak Company Information
12.3.2 Bespak Business Overview
12.3.3 Bespak Revenue in Inhalation CDMO Business (2020-2025)
12.3.4 Bespak Inhalation CDMO Product Portfolio
12.3.5 Bespak Recent Developments
12.4 Catalent
12.4.1 Catalent Company Information
12.4.2 Catalent Business Overview
12.4.3 Catalent Revenue in Inhalation CDMO Business (2020-2025)
12.4.4 Catalent Inhalation CDMO Product Portfolio
12.4.5 Catalent Recent Developments
12.5 CritiTech
12.5.1 CritiTech Company Information
12.5.2 CritiTech Business Overview
12.5.3 CritiTech Revenue in Inhalation CDMO Business (2020-2025)
12.5.4 CritiTech Inhalation CDMO Product Portfolio
12.5.5 CritiTech Recent Developments
12.6 Enteris Biopharma
12.6.1 Enteris Biopharma Company Information
12.6.2 Enteris Biopharma Business Overview
12.6.3 Enteris Biopharma Revenue in Inhalation CDMO Business (2020-2025)
12.6.4 Enteris Biopharma Inhalation CDMO Product Portfolio
12.6.5 Enteris Biopharma Recent Developments
12.7 Experic
12.7.1 Experic Company Information
12.7.2 Experic Business Overview
12.7.3 Experic Revenue in Inhalation CDMO Business (2020-2025)
12.7.4 Experic Inhalation CDMO Product Portfolio
12.7.5 Experic Recent Developments
12.8 HCmed
12.8.1 HCmed Company Information
12.8.2 HCmed Business Overview
12.8.3 HCmed Revenue in Inhalation CDMO Business (2020-2025)
12.8.4 HCmed Inhalation CDMO Product Portfolio
12.8.5 HCmed Recent Developments
12.9 Hovione
12.9.1 Hovione Company Information
12.9.2 Hovione Business Overview
12.9.3 Hovione Revenue in Inhalation CDMO Business (2020-2025)
12.9.4 Hovione Inhalation CDMO Product Portfolio
12.9.5 Hovione Recent Developments
12.10 Iconovo
12.10.1 Iconovo Company Information
12.10.2 Iconovo Business Overview
12.10.3 Iconovo Revenue in Inhalation CDMO Business (2020-2025)
12.10.4 Iconovo Inhalation CDMO Product Portfolio
12.10.5 Iconovo Recent Developments
12.11 Kindeva
12.11.1 Kindeva Company Information
12.11.2 Kindeva Business Overview
12.11.3 Kindeva Revenue in Inhalation CDMO Business (2020-2025)
12.11.4 Kindeva Inhalation CDMO Product Portfolio
12.11.5 Kindeva Recent Developments
12.12 Lonza
12.12.1 Lonza Company Information
12.12.2 Lonza Business Overview
12.12.3 Lonza Revenue in Inhalation CDMO Business (2020-2025)
12.12.4 Lonza Inhalation CDMO Product Portfolio
12.12.5 Lonza Recent Developments
12.13 Particle Sciences
12.13.1 Particle Sciences Company Information
12.13.2 Particle Sciences Business Overview
12.13.3 Particle Sciences Revenue in Inhalation CDMO Business (2020-2025)
12.13.4 Particle Sciences Inhalation CDMO Product Portfolio
12.13.5 Particle Sciences Recent Developments
12.14 Proveris
12.14.1 Proveris Company Information
12.14.2 Proveris Business Overview
12.14.3 Proveris Revenue in Inhalation CDMO Business (2020-2025)
12.14.4 Proveris Inhalation CDMO Product Portfolio
12.14.5 Proveris Recent Developments
12.15 Recipharm
12.15.1 Recipharm Company Information
12.15.2 Recipharm Business Overview
12.15.3 Recipharm Revenue in Inhalation CDMO Business (2020-2025)
12.15.4 Recipharm Inhalation CDMO Product Portfolio
12.15.5 Recipharm Recent Developments
12.16 Renejix
12.16.1 Renejix Company Information
12.16.2 Renejix Business Overview
12.16.3 Renejix Revenue in Inhalation CDMO Business (2020-2025)
12.16.4 Renejix Inhalation CDMO Product Portfolio
12.16.5 Renejix Recent Developments
12.17 Ritedose
12.17.1 Ritedose Company Information
12.17.2 Ritedose Business Overview
12.17.3 Ritedose Revenue in Inhalation CDMO Business (2020-2025)
12.17.4 Ritedose Inhalation CDMO Product Portfolio
12.17.5 Ritedose Recent Developments
12.18 Vectura
12.18.1 Vectura Company Information
12.18.2 Vectura Business Overview
12.18.3 Vectura Revenue in Inhalation CDMO Business (2020-2025)
12.18.4 Vectura Inhalation CDMO Product Portfolio
12.18.5 Vectura Recent Developments
12.19 Sanner
12.19.1 Sanner Company Information
12.19.2 Sanner Business Overview
12.19.3 Sanner Revenue in Inhalation CDMO Business (2020-2025)
12.19.4 Sanner Inhalation CDMO Product Portfolio
12.19.5 Sanner Recent Developments
13 Report Conclusion
14 Disclaimer
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
Table 4. Market Value Comparison by Application (2020 VS 2024 VS 2031) & (US$ Million)
Table 5. Global Inhalation CDMO Market Size by Type (2020-2025) & (US$ Million)
Table 6. Global Inhalation CDMO Revenue Market Share by Type (2020-2025)
Table 7. Global Inhalation CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 8. Global Inhalation CDMO Revenue Market Share by Type (2026-2031)
Table 9. Global Inhalation CDMO Market Size by Application (2020-2025) & (US$ Million)
Table 10. Global Inhalation CDMO Revenue Market Share by Application (2020-2025)
Table 11. Global Inhalation CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 12. Global Inhalation CDMO Revenue Market Share by Application (2026-2031)
Table 13. Global Inhalation CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 14. Global Inhalation CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 15. Global Inhalation CDMO Market Share by Region (2020-2025)
Table 16. Global Inhalation CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 17. Global Inhalation CDMO Market Share by Region (2026-2031)
Table 18. Inhalation CDMO Industry Trends
Table 19. Inhalation CDMO Industry Drivers
Table 20. Inhalation CDMO Industry Opportunities and Challenges
Table 21. Inhalation CDMO Market Restraints
Table 22. Global Top Inhalation CDMO Players by Revenue (US$ Million) & (2020-2025)
Table 23. Global Inhalation CDMO Revenue Market Share by Players (2020-2025)
Table 24. Global Inhalation CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
Table 25. Global Key Players of Inhalation CDMO, Headquarters and Area Served
Table 26. Global Inhalation CDMO Players, Product Type & Application
Table 27. Global Players Market Concentration Ratio (CR5 and HHI)
Table 28. Global Inhalation CDMO by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2024)
Table 29. Players Mergers & Acquisitions, Expansion Plans
Table 30. North America Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 31. North America Inhalation CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 32. North America Inhalation CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 33. Europe Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 34. Europe Inhalation CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 35. Europe Inhalation CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 36. Asia Pacific Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 37. Asia Pacific Inhalation CDMO Market Size by Region (2020-2025) & (US$ Million)
Table 38. Asia Pacific Inhalation CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 39. South America Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 40. South America Inhalation CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 41. South America Inhalation CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 42. Middle East & Africa Inhalation CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Middle East & Africa Inhalation CDMO Market Size by Country (2020-2025) & (US$ Million)
Table 44. Middle East & Africa Inhalation CDMO Market Size by Country (2026-2031) & (US$ Million)
Table 45. Company One Company Information
Table 46. Company One Business Overview
Table 47. Company One Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 48. Company One Inhalation CDMO Product Portfolio
Table 49. Company One Recent Developments
Table 50. Company Two Company Information
Table 51. Company Two Business Overview
Table 52. Company Two Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 53. Company Two Inhalation CDMO Product Portfolio
Table 54. Company Two Recent Developments
Table 55. Company Three Company Information
Table 56. Company Three Business Overview
Table 57. Company Three Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 58. Company Three Inhalation CDMO Product Portfolio
Table 59. Company Three Recent Developments
Table 60. Company Four Company Information
Table 61. Company Four Business Overview
Table 62. Company Four Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 63. Company Four Inhalation CDMO Product Portfolio
Table 64. Company Four Recent Developments
Table 65. Company Five Company Information
Table 66. Company Five Business Overview
Table 67. Company Five Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 68. Company Five Inhalation CDMO Product Portfolio
Table 69. Company Five Recent Developments
Table 70. Company Six Company Information
Table 71. Company Six Business Overview
Table 72. Company Six Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 73. Company Six Inhalation CDMO Product Portfolio
Table 74. Company Six Recent Developments
Table 75. Company Seven Company Information
Table 76. Company Seven Business Overview
Table 77. Company Seven Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 78. Company Seven Inhalation CDMO Product Portfolio
Table 79. Company Seven Recent Developments
Table 80. Company Eight Company Information
Table 81. Company Eight Business Overview
Table 82. Company Eight Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 83. Company Eight Inhalation CDMO Product Portfolio
Table 84. Company Eight Recent Developments
Table 85. Company Nine Company Information
Table 86. Company Nine Business Overview
Table 87. Company Nine Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 88. Company Nine Inhalation CDMO Product Portfolio
Table 89. Company Nine Recent Developments
Table 90. Company Ten Company Information
Table 91. Company Ten Business Overview
Table 92. Company Ten Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 93. Company Ten Inhalation CDMO Product Portfolio
Table 94. Company Ten Recent Developments
Table 95. Company 11 Company Information
Table 96. Company 11 Business Overview
Table 97. Company 11 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 98. Company 11 Inhalation CDMO Product Portfolio
Table 99. Company 11 Recent Developments
Table 100. Company 12 Company Information
Table 101. Company 12 Business Overview
Table 102. Company 12 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 103. Company 12 Inhalation CDMO Product Portfolio
Table 104. Company 12 Recent Developments
Table 105. Company 13 Company Information
Table 106. Company 13 Business Overview
Table 107. Company 13 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 108. Company 13 Inhalation CDMO Product Portfolio
Table 109. Company 13 Recent Developments
Table 110. Company 14 Company Information
Table 111. Company 14 Business Overview
Table 112. Company 14 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 113. Company 14 Inhalation CDMO Product Portfolio
Table 114. Company 14 Recent Developments
Table 115. Company 15 Company Information
Table 116. Company 15 Business Overview
Table 117. Company 15 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 118. Company 15 Inhalation CDMO Product Portfolio
Table 119. Company 15 Recent Developments
Table 120. Company 16 Company Information
Table 121. Company 16 Business Overview
Table 122. Company 16 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 123. Company 16 Inhalation CDMO Product Portfolio
Table 124. Company 16 Recent Developments
Table 125. Company 17 Company Information
Table 126. Company 17 Business Overview
Table 127. Company 17 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 128. Company 17 Inhalation CDMO Product Portfolio
Table 129. Company 17 Recent Developments
Table 130. Company 18 Company Information
Table 131. Company 18 Business Overview
Table 132. Company 18 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 133. Company 18 Inhalation CDMO Product Portfolio
Table 134. Company 18 Recent Developments
Table 135. Company 19 Company Information
Table 136. Company 19 Business Overview
Table 137. Company 19 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 138. Company 19 Inhalation CDMO Product Portfolio
Table 139. Company 19 Recent Developments
Table 140. Company 20 Company Information
Table 141. Company 20 Business Overview
Table 142. Company 20 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 143. Company 20 Inhalation CDMO Product Portfolio
Table 144. Company 20 Recent Developments
Table 145. Company 21 Company Information
Table 146. Company 21 Business Overview
Table 147. Company 21 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 148. Company 21 Inhalation CDMO Product Portfolio
Table 149. Company 21 Recent Developments
Table 150. Company 22 Company Information
Table 151. Company 22 Business Overview
Table 152. Company 22 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 153. Company 22 Inhalation CDMO Product Portfolio
Table 154. Company 22 Recent Developments
Table 155. Company 23 Company Information
Table 156. Company 23 Business Overview
Table 157. Company 23 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 158. Company 23 Inhalation CDMO Product Portfolio
Table 159. Company 23 Recent Developments
Table 160. Company 24 Company Information
Table 161. Company 24 Business Overview
Table 162. Company 24 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 163. Company 24 Inhalation CDMO Product Portfolio
Table 164. Company 24 Recent Developments
Table 165. Company 25 Company Information
Table 166. Company 25 Business Overview
Table 167. Company 25 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 168. Company 25 Inhalation CDMO Product Portfolio
Table 169. Company 25 Recent Developments
Table 170. Company 26 Company Information
Table 171. Company 26 Business Overview
Table 172. Company 26 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 173. Company 26 Inhalation CDMO Product Portfolio
Table 174. Company 26 Recent Developments
Table 175. Company 27 Company Information
Table 176. Company 27 Business Overview
Table 177. Company 27 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 178. Company 27 Inhalation CDMO Product Portfolio
Table 179. Company 27 Recent Developments
Table 180. Company 28 Company Information
Table 181. Company 28 Business Overview
Table 182. Company 28 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 183. Company 28 Inhalation CDMO Product Portfolio
Table 184. Company 28 Recent Developments
Table 185. Company 29 Company Information
Table 186. Company 29 Business Overview
Table 187. Company 29 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 188. Company 29 Inhalation CDMO Product Portfolio
Table 189. Company 29 Recent Developments
Table 190. Company 30 Company Information
Table 191. Company 30 Business Overview
Table 192. Company 30 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 193. Company 30 Inhalation CDMO Product Portfolio
Table 194. Company 30 Recent Developments
Table 195. Company 31 Company Information
Table 196. Company 31 Business Overview
Table 197. Company 31 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 198. Company 31 Inhalation CDMO Product Portfolio
Table 199. Company 31 Recent Developments
Table 200. Company 32 Company Information
Table 201. Company 32 Business Overview
Table 202. Company 32 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 203. Company 32 Inhalation CDMO Product Portfolio
Table 204. Company 32 Recent Developments
Table 205. Company 33 Company Information
Table 206. Company 33 Business Overview
Table 207. Company 33 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 208. Company 33 Inhalation CDMO Product Portfolio
Table 209. Company 33 Recent Developments
Table 210. Company 34 Company Information
Table 211. Company 34 Business Overview
Table 212. Company 34 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 213. Company 34 Inhalation CDMO Product Portfolio
Table 214. Company 34 Recent Developments
Table 215. Company 35 Company Information
Table 216. Company 35 Business Overview
Table 217. Company 35 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 218. Company 35 Inhalation CDMO Product Portfolio
Table 219. Company 35 Recent Developments
Table 220. Company 36 Company Information
Table 221. Company 36 Business Overview
Table 222. Company 36 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 223. Company 36 Inhalation CDMO Product Portfolio
Table 224. Company 36 Recent Developments
Table 225. Company 37 Company Information
Table 226. Company 37 Business Overview
Table 227. Company 37 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 228. Company 37 Inhalation CDMO Product Portfolio
Table 229. Company 37 Recent Developments
Table 230. Company 38 Company Information
Table 231. Company 38 Business Overview
Table 232. Company 38 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 233. Company 38 Inhalation CDMO Product Portfolio
Table 234. Company 38 Recent Developments
Table 235. Company 39 Company Information
Table 236. Company 39 Business Overview
Table 237. Company 39 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 238. Company 39 Inhalation CDMO Product Portfolio
Table 239. Company 39 Recent Developments
Table 240. Company 40 Company Information
Table 241. Company 40 Business Overview
Table 242. Company 40 Revenue in Inhalation CDMO Business (2020-2025) & (US$ Million)
Table 243. Company 40 Inhalation CDMO Product Portfolio
Table 244. Company 40 Recent Developments
Table 245. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Inhalation CDMO Product Image
Figure 5. Global Inhalation CDMO Market Size Comparison by Type (2025-2031) & (US$ Million)
Figure 6. Global Inhalation CDMO Market Share by Type: 2024 VS 2031
Figure 7. Soft Mist Inhalers (SMIs) Product
Figure 8. Dry Powder Inhalers (DPIs) Product
Figure 9. Metered Dose Inhalers (MDIs) Product
Figure 10. Others Product
Figure 11. Global Inhalation CDMO Market Size by Application (2025-2031) & (US$ Million)
Figure 12. Global Inhalation CDMO Market Share by Application: 2024 VS 2031
Figure 13. Commercial Product
Figure 14. Academic Research Product
Figure 15. Others Product
Figure 16. Global Inhalation CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Inhalation CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Inhalation CDMO Market Share by Region: 2024 VS 2031
Figure 19. Global Inhalation CDMO Market Share by Players in 2024
Figure 20. Global Inhalation CDMO Manufacturers Established Date
Figure 21. Global Top 5 and 10 Inhalation CDMO Players Market Share by Revenue in 2024
Figure 22. Players Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 23. North America Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. North America Inhalation CDMO Market Share by Country (2020-2031)
Figure 25. United States Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Canada Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Mexico Inhalation CDMO Market Share by Country (2020-2031)
Figure 28. Europe Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Europe Inhalation CDMO Market Share by Country (2020-2031)
Figure 30. Germany Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. France Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. U.K. Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Italy Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Spain Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Russia Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Netherlands Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Nordic Countries Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Asia-Pacific Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Asia-Pacific Inhalation CDMO Market Share by Country (2020-2031)
Figure 40. China Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Japan Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. South Korea Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. India Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. India Inhalation CDMO Market Share by Country (2020-2031)
Figure 45. Australia Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. China Taiwan Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Southeast Asia Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. South America Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. South America Inhalation CDMO Market Share by Country (2020-2031)
Figure 50. Brazil Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Argentina Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 52. Chile Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 53. Colombia Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 54. Peru Inhalation CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 55. Aptar Pharma Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 56. Bend Bioscience Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 57. Bespak Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 58. Catalent Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 59. CritiTech Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 60. Enteris Biopharma Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 61. Experic Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 62. HCmed Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 63. Hovione Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 64. Iconovo Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 65. Kindeva Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 66. Lonza Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 67. Particle Sciences Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 68. Proveris Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 69. Recipharm Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 70. Renejix Revenue Growth Rate in Inhalation CDMO Business (2020-2025)
Figure 71. Ritedose Revenue Growth Rate in Inhalation CDMO Business (2020-2025)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings